The impact of targeted therapy on management of metastatic renal cell carcinoma: Trends in systemic therapy and cytoreductive nephrectomy utilization

Sarah P. Psutka, Simon P. Kim, Cary P. Gross, Holly Van Houten, R. Houston Thompson, Robert Abouassaly, Christopher Weight, Stephen A. Boorjian, Bradley C. Leibovich, Nilay D. Shah

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Objective To describe the dissemination of targeted therapy and its impact on rates of cytoreductive nephrectomy (CNx) and among privately insured patients with metastatic renal cell carcinoma (mRCC). Patients and Methods All mRCC patients aged <65 years with systemic therapy from 2004 to 2010 (n = 610) were identified from a large private insurance database. Trends in the relative utilization of immunotherapy and targeted therapy, as well as CNx treatment patterns, were compared between early (2004-2007) and late (2008-2010) periods. Multivariate logistic regression analysis identified predictors of CNx, and adjusted predicted probabilities of CNx were compared. Results Among the 610 patients, 535 (87.7%) and 43 (7.1%) patients received targeted or immunotherapy alone, whereas 32 patients (5.2%) received both. A total of 145 patients (23.8%) underwent CNx. From 2004 to 2010, the annual rate of targeted therapy utilization increased markedly (from 10% to 98.2%; P <.001), whereas immunotherapy receipt declined (from 100% to 1.9%; P <.001). Annual CNx utilization peaked at 31.3% in 2005, and declined to 14.8% by 2010 (P =.045). Independent predictors receipt of CNx on multivariate analysis included age >55 years (odds ratio, 0.80; 95% confidence interval, 0.66-0.96; P =.02) and female gender (odds ratio, 0.79; 95% confidence interval, 0.63-0.99; P =.04). Notably, the predicted probability of CNx decreased between the early and late period among patients irrespective of age, gender, targeted therapy, or number of systemic therapies (P <.001 for all). Conclusion During this study period, targeted therapy has largely supplanted the use of immunotherapy among privately insured patients with mRCC treated with systemic therapy, whereas rates of CNx have declined steadily since 2005.

Original languageEnglish (US)
Pages (from-to)442-451
Number of pages10
Issue number2
StatePublished - Feb 1 2015

Bibliographical note

Funding Information:
Financial Disclosure: Cary P. Gross received research funding from Medtronic , Johnson & Johnson , and 21st Century Oncology . The remaining authors declare that they have no relevant financial interests.

Publisher Copyright:
© 2015 Elsevier Inc. All Rights Reserved.


Dive into the research topics of 'The impact of targeted therapy on management of metastatic renal cell carcinoma: Trends in systemic therapy and cytoreductive nephrectomy utilization'. Together they form a unique fingerprint.

Cite this